To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:279 Issue:1 Number:3 ISSN#:2564-2537
RCT
ACE Report #14845
Ace Report Cover Osteoarthritis

Thai Medicinal Plant-4 Cream vs. Diclofenac Gel for Knee Osteoarthritis


How to Cite

OrthoEvidence. Thai Medicinal Plant-4 Cream vs. Diclofenac Gel for Knee Osteoarthritis . ACE Report. 2022;279(1):3. Available from: https://myorthoevidence.com/AceReport/Report/14845

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

A Randomized Controlled Trial of Thai Medicinal Plant-4 Cream versus Diclofenac Gel in the Management of Symptomatic Osteoarthritis of the Knee

Evid Based Complement Alternat Med . 2022 Jun 13;2022:8657000.

Contributing Authors:
N Koonrungsesomboon A Churyen S Teekachunhatean C Sangdee N Hanprasertpong

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Two hundred patients with symptomatic osteoarthritis of the knee were randomized to receive either Thai medicinal plant-4 (TMP-4) cream (n=100) or diclofenac gel (n=99). Outcomes that were assessed in this trial were Visual Analog Scale (VAS) scores for knee pain and stiffness, 10-step stair climb test, timed up and go, and Knee Injury and Osteoarthritis Outcome Score (KOOS) at 2 and 4 weeks. The ...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

MOC Section 2 Self Learning (CAN - Royal College)

You’re eligible to earn 0.5 CME credits for reading this report.

Generating CME Eligible Questions

I was looking for information about:

How does this evidence apply to your practice?

Save

Congratulations, ! You've earned 0.5 CME credits.
Click below to submit your completed credits.

Submit Credits

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.